Anzeige
Mehr »
Dienstag, 16.09.2025 - Börsentäglich über 12.000 News
Die Ethereum-Vorreiter: Wie Republic Technologies die Infrastruktur der Zukunft aufbaut
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
136 Leser
Artikel bewerten:
(0)

Q Core Medical Opens European Hub in France, Kicks Off Direct Sales of Leading Infusion Systems

New office to be led by industry veteran Laurent Schektman

NETANYA, Israel, Feb. 27, 2019 /PRNewswire/ -- Q Core Medical, a leading developer of smart infusion systems for hospital and ambulatory care settings, today announced the opening of a new European office in Marseille, France. The new European regional headquarters will be led by Q Core Medical Country Manager, Laurent Schektman, who will lead direct sales efforts of Q Core's hospital and homecare infusion systems in France and other European markets.

"It is a privilege to provide Q Core Medical's advanced infusion systems to French and European healthcare facilities from our new office in Marseille, the doorway to the French and European healthcare markets," said Laurent Schektman, Q Core Medical Country Manager. "France is especially ready for Q Core's level of infusion system innovation. With a growing elderly population, an increased need for infusion, and a 5-10% increase in patients being treated in homecare settings rather than hospitals, France has a real market need for intuitive, easy-to-use and reliable infusion systems."

Q Core's flagship Sapphire infusion pumps provide light-weight, advanced and intuitive infusion systems with diverse functionality appreciated by caregivers and patients. Its systems can be used in pain management, oncology drug delivery, epidural infusion, parenteral nutrition, antibiotic treatments among other IV therapies. The Sapphire infusion family can be used for large volume and ambulatory infusions in hospitals, as well as treatment in homecare and alternate site settings.

"We are pleased to see a growing global health technology company choose Marseille as its European headquarters," said Maribel Sierra, Project Manager from Provence Promotion, the Aix-Marseille-Provence metropolis economic development agency. "Marseille is ideally situated to serve as a hub for doing business in Europe and Africa, as well as granting easy access to Mediterranean markets. Q Core serves as a prime example of the business opportunities present in the South of France for thriving health and technology players."

France's healthcare system, based on advanced reimbursement models, is following the global shift of moving patients from hospitals into homecare settings. The French government is building regulation in the homecare market, with strong economics models to bolster this shift. A reduction in the average length of stay in hospitals, a growing elderly patient population with chronic diseases, a higher level of comfort at home for patients, and a lower cost of home health services has resulted in a 40 percent year-on-year growth of patients receiving homecare treatments over the past four years.

"We are delighted to directly market our pioneering infusion pump systems in France, expanding our physical footprint into such a vital regional market," said Tally Eitan, President of Q Core Medical. "Laurent's previous work experiences at Abbott, Hospira, Pfizer and ICU Medical give him vast knowledge of the French and European healthcare landscapes. With Laurent at the helm of our European operations, with his passion and commitment to the French healthcare market, we are confident that we will be able to meet the evolving infusion needs across the continuum of care."

About Q Core Medical
Q Core Medical is an infusion solutions provider meeting the evolving infusion needs of ambulatory care and hospital markets. Q Core Medical's flagship Sapphire infusion pump systems are marketed globally with fleets operating in North America, Europe, Asia, South America and Australia for the last decade. One of three privately held companies operating under the Eitan Group, Q Core Medical designs, develops, manufactures and markets advanced, future-ready infusion systems. For more information, visit http://www.qcore.com/.

Follow Q Core Medical on LinkedIn and Twitter.

Media Relations Contact:
Nicole Grubner
Finn Partners
+1-929-222-8011
nicole.grubner@finnpartners.com

Company Contact:
+972-732388888
info@qcore.com

Q Core Medical France
+33-4-91134599
dispositifsmedicaux@Qcore.fr

© 2019 PR Newswire
Solarbranche vor dem Mega-Comeback?
Lange galten Solaraktien als Liebling der Börse, dann kam der herbe Absturz: Zinsschock, Überkapazitäten aus China und ein Preisverfall, der selbst Marktführer wie SMA Solar, Enphase Energy oder SolarEdge massiv unter Druck setzte. Viele Anleger haben der Branche längst den Rücken gekehrt.

Doch genau das könnte jetzt die Chance sein!
Die Kombination aus KI-Explosion und Energiewende bringt die Branche zurück ins Rampenlicht:
  • Rechenzentren verschlingen Megawatt – Solarstrom bietet den günstigsten Preis je Kilowattstunde
  • Moderne Module liefern Wirkungsgrade wie Atomkraftwerke
  • hina bremst Preisdumping & pusht massiv den Ausbau
Gleichzeitig locken viele Solar-Aktien mit historischen Tiefstständen und massiven Short-Quoten, ein perfekter Nährboden für Kursrebound und Squeeze-Rally.

In unserem exklusiven Gratis-Report zeigen wir dir, welche 4 Solar-Aktien besonders vom Comeback profitieren dürften und warum jetzt der perfekte Zeitpunkt für einen Einstieg sein könnte.

Laden Sie jetzt den Spezialreport kostenlos herunter, bevor die Erholung am Markt beginnt!

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.